|Videos|November 3, 2018
Rolf Fronczek, PhD, MD: Narcolepsy and Opiates
Author(s)Rolf Fronczek, PhD, MD
The neurologist discussed an analysis of findings suggesting that opiate agonists may have a role in the treatment of narcolepsy.
Advertisement
“This could also have clinical implications not only for opiate users, maybe as an explanation for their addiction, but also for narcolepsy, maybe as a treatment.”
Rolf Fronczek, PhD, MD, Department of Neurology, Leiden University Medical Centre, Sleep-Wake Centre SEIN, sat with NeurologyLive at the 24th Congress of the European Sleep Research Society in Basel, Switzerland, to discuss the connection between narcolepsy and opiates.
In a collaboration with researchers from UCLA, Fronczek and colleagues examined a number of hypocretin neurons in postmortem brains and found that some individuals presented with an unexpectedly large cell number increase. Looking back, researchers discovered that those patients were opiate addicts. Similar increases in hypocretin-producing cells were induced in a mouse model by administration of morphine.
With an interest in these findings, Fronczek and colleagues examined cases of individuals with narcolepsy from the Dutch Brain Bank. Similar to previous findings, researchers found that in 1 patient where hypocretin neurons were present, the individual did in fact use opiates and experienced an improvement in narcolepsy symptoms during the time period. There was about a 50% return of hypocretin neurons compared to a typical narcoleptic brain where there are hardly any neurons left.
The clinical implications of these findings may not only be relevant for opiate users, as an increased number of hypocretin-producing cells may play a role in maintaining opiate addiction, but also raises the question about a potential treatment option for narcolepsy.
REFERENCE
Thannickal T, John J, Shan L, et al. Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Science Translational Medicine. 2018;10(447).
doi
: 10.1126/scitranslmed.aao4953.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
3
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
4
2025 Women in Neurology Conference: Educating, Mentoring, and Networking
5